How Bio-Techne's Spatial Biology COMET Expansion (TECH) Has Changed Its Investment Story
Bio-Techne recently expanded its COMET spatial biology portfolio with new SPYRE Focus Panels, SPYRE Amplification Kits, and upgraded HORIZON image analysis software. This move aims to enhance automated, modular tissue analysis and deepen the company's high-content spatial biology offerings. While this expansion reinforces Bio-Techne's long-term investment narrative focused on specialized tools, near-term challenges such as funding pressures in biotech and academia remain, making execution on higher-margin platforms crucial for earnings growth.
Evaluating Danaher (DHR) After Mixed Recent Returns And Conflicting Undervaluation Signals
Danaher (DHR) is currently facing mixed investor sentiment due to a year of positive returns contrasted with recent declines over the last three months and month, alongside a 4.5% uptick in the past week. Despite having a projected fair value of $264.91, suggesting it's 27.5% undervalued, other analyses indicate a 13.2% undervaluation but with an expensive P/E ratio. The article advises investors to further analyze the company's prospects given these conflicting signals and potential risks.
Fulton Breakefield Broenniman LLC Reduces Stock Holdings in Danaher Corporation $DHR
Fulton Breakefield Broenniman LLC significantly reduced its stake in Danaher Corporation by 27.9% in Q4, selling 18,647 shares and retaining 48,301 shares valued at $11.06 million. The article also notes Danaher's strong Q4 earnings, surpassing analyst estimates, and a recent dividend increase from $0.32 to $0.40 per share, yielding 0.8%. Analysts maintain a "Moderate Buy" rating for Danaher, with an average price target of $253.79.
Verra Mobility (NASDAQ: VRRM) details 2026 proxy, pay plan and 2025 results
Verra Mobility (NASDAQ: VRRM) has released details for its 2026 annual meeting, including proposals for electing three Class II directors, advisory votes on executive compensation and its frequency, and the ratification of Deloitte & Touche LLP as its independent auditor. The company reported strong financial performance for fiscal year 2025, with revenues of $979.1 million and Adjusted EBITDA of $415.9 million. The proxy statement also details the compensation philosophy, which is heavily performance-based, and outlines a new five-year long-term incentive program for executives.
Danaher (DHR) Analyst Rating: Evercore ISI Lowers Price Target
Evercore ISI Group has maintained an "Outperform" rating for Danaher (DHR) but lowered its price target from $254.00 to $225.00, an 11.42% decrease. Despite this adjustment, the overall analyst consensus for Danaher remains positive. Danaher, specializing in scientific instruments and consumables, shows an average target price of $262.62 from 20 analysts and an "Outperform" recommendation from 26 brokerage firms.
Danaher (DHR) Analyst Rating: Evercore ISI Lowers Price Target
Evercore ISI Group has maintained its "Outperform" rating for Danaher (DHR) but lowered its price target from $254.00 to $225.00, a decrease of 11.42%. Despite this adjustment, the overall analyst consensus for Danaher remains positive, with an average target price of $262.62 from 20 analysts, suggesting a significant upside from the current price. GuruFocus also estimates a fair value for DHR at $248.44.
Danaher Corporation (DHR) Stock Forecasts
This page is a privacy consent form from Yahoo that discusses the use of cookies and personal data. It explains that Yahoo and its partners use cookies for site functionality, security, user authentication, and analytics. Users are given options to accept all cookies, reject all cookies, or manage their privacy settings.
Danaher’s Profit Report Challenge: Will First Quarter 2026 Address the Valuation Discrepancy Caused by Masimo?
Danaher (DHR) shares are facing a significant valuation discrepancy, with a high price-to-earnings ratio suggesting optimism despite a nearly 20% drop in 2026. This decline is largely attributed to investor skepticism following the acquisition of Masimo, which introduced new risks and challenged traditional views of Danaher's business model. The upcoming Q1 2026 earnings report on April 21st will be critical in determining if the company can demonstrate sufficient revenue growth to bridge the gap between investor expectations and current performance.
Electron Microscopes Market Is Going to Boom |• Thermo Fisher Scientific • JEOL Ltd.
Worldwide Market Reports has released a comprehensive research study on the Electron Microscopes Market, forecasting its growth from 2026 to 2033. The report, developed using primary and secondary research, details market size, competitive landscape, key players like Thermo Fisher Scientific and JEOL Ltd., and segmentation by type and application. It also provides insights into regional trends, growth drivers, challenges, and opportunities for stakeholders.
Evercore ISI Adjusts Danaher Price Target to $225 From $254, Maintains Outperform Rating
Evercore ISI has adjusted its price target for Danaher Corporation (DHR) to $225, down from $254, while reiterating an "Outperform" rating on the stock. Danaher is a diversified industrial and technology group focused on diagnostic, life sciences, and biotechnology equipment. The company's net sales are geographically distributed, with significant portions in the United States, China, and other international markets.
Rathbones Group PLC Has $60.78 Million Stock Holdings in Danaher Corporation $DHR
Rathbones Group PLC reduced its stake in Danaher Corporation by 5.0% in the fourth quarter, selling 13,971 shares but still holding 265,499 shares valued at approximately $60.78 million. Danaher recently increased its quarterly dividend to $0.40 per share, resulting in an annualized dividend of $1.60 and a yield of 0.8%. The company also exceeded Wall Street's Q4 earnings and revenue estimates, reporting $2.23 EPS and $6.84 billion in revenue with a positive consensus price target of $253.55 from analysts.
Major Investors Accumulate Danaher Shares Amid Price Weakness
Major institutional investors are increasing their holdings in Danaher despite recent price weakness, seeing it as an opportune time to buy before its annual low. The company's upcoming Q1 earnings report on April 21, 2026, and its strategic $9.9 billion acquisition of Masimo, are key factors drawing investor attention and maintaining a "Moderate Buy" analyst consensus. This acquisition is expected to bolster Danaher's diagnostics segment and expand its technological portfolio.
Thermo Fisher Microscopes: Precision in Scientific Imaging
This article details how Thermo Fisher microscopes are crucial for scientific imaging across various research and industrial applications. It highlights their advanced optical and electron models, cutting-edge features like high-resolution optics, fluorescence capabilities, and automation. The article also discusses their market relevance, competitive landscape, ongoing innovations, and significant impact on global health and scientific discovery.
Danaher's Strategic Ambitions: A Pivotal Period Ahead
Danaher Corporation is at a critical juncture, facing the integration of its $9.9 billion Masimo acquisition and an imminent quarterly earnings report. Despite competitive pressures and a 20% gap from its 52-week high, analysts see upside potential, with the stock potentially undervalued. The market will be closely watching how Danaher balances this major expansion with its consistent dividend payments and long-term growth strategy.
Global Trust Asset Management LLC Grows Position in Danaher Corporation $DHR
Global Trust Asset Management LLC significantly increased its stake in Danaher Corporation by 719.8% in Q4, acquiring 5,694 additional shares and bringing its total holdings to 6,485 shares valued at approximately $1.485 million. Analysts maintain a "Moderate Buy" rating for Danaher, with a consensus price target of $253.55, following the company's Q4 earnings beat and a dividend increase. The company reported EPS of $2.23 and revenue of $6.84 billion, surpassing estimates.
DGX Stock News Today | Earnings, Events & Price Alerts
This article provides recent news and event updates for Quest Diagnostics (DGX), including their upcoming Q1 2026 financial results announcement and the launch of an AI companion for lab data analysis. It also highlights leadership appointments, dividend increases, and stock performance milestones for the company.
Danaher Corporation (1DHR.MI) stock price, news, quote and history
This page provides comprehensive information on Danaher Corporation (1DHR.MI), including its stock price, news, quotes, and historical data. It offers an overview of the company's operations across Biotechnology, Life Sciences, and Diagnostics segments, along with key financial statistics, performance metrics, and comparison tools with similar companies.
Danaher Corporation $DHR Shares Bought by Aberdeen Group plc
Aberdeen Group plc increased its stake in Danaher Corporation (NYSE:DHR) by 12.0% in the fourth quarter, now owning 1.29 million shares valued at approximately $295.9 million. This transaction is part of a broader trend of institutional investors holding a significant portion, about 79.05%, of Danaher's stock. The company's recent strong financial performance, increased dividend, and positive analyst ratings contribute to a "Moderate Buy" consensus.
Danaher Corp. Experiences Valuation Adjustment Amid Competitive Market Landscape
Danaher Corp., a significant player in the Pharmaceuticals & Biotechnology sector, has seen a valuation adjustment with its stock price at $190.79, reflecting a -4.79% return over the past year. The company's financial metrics include a P/E ratio of 41 and a dividend yield of 0.54%, indicating a competitive position but also challenges in growth compared to its peers like Abbott Laboratories and Thermo Fisher Scientific.
AAV Genome Sequencing Service Market Is Booming Rapidly with Strong Demand By 2033 | Thermo Fisher Scientific, Illumina, Danaher Corporation
Coherent Market Insights has published a new research study on the Global "AAV Genome Sequencing Service Market" forecasting growth through 2033. The report segments the market by type, application, end-user, and region, identifying key players like Thermo Fisher Scientific, Illumina, and Danaher Corporation. It aims to provide a comprehensive analysis of market trends, drivers, restraints, competitive landscape, and regional dynamics to aid strategic decision-making.
Triad Investment Management Purchases New Stake in Danaher Corporation $DHR
Triad Investment Management has acquired a new stake in Danaher Corporation, purchasing 21,540 shares valued at approximately $4.93 million, making it their sixth-largest position. Other institutional investors have also increased their holdings in Danaher, which recently exceeded quarterly earnings and revenue estimates and raised its quarterly dividend. The company maintains a "Moderate Buy" rating from analysts with an average target price of $253.55.
Bank Pictet & Cie Europe AG Boosts Stock Position in Danaher Corporation $DHR
Bank Pictet & Cie Europe AG significantly increased its stake in Danaher Corporation by 25.4% during the fourth quarter, making DHR its 15th largest holding. Several other hedge funds also adjusted their positions in Danaher, which recently reported strong earnings, beating analyst estimates, and increased its quarterly dividend. The company's stock shows a "Moderate Buy" consensus rating from analysts with an average target price of $253.55.
Banque Pictet & Cie SA Purchases 79,407 Shares of Danaher Corporation $DHR
Banque Pictet & Cie SA significantly increased its stake in Danaher Corporation (NYSE:DHR) during the fourth quarter, acquiring an additional 79,407 shares, bringing its total holdings to 140,037 shares valued at approximately $32.06 million. Danaher reported strong Q4 earnings, beating analyst expectations with $2.23 EPS and $6.84 billion in revenue, and has also increased its quarterly dividend to $0.40 per share. Analysts maintain a "Moderate Buy" rating for the stock, with an average target price of $253.55.
SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--VYNE, MASI, IBCP, and HCBN
Monteverde & Associates PC, a class action firm, is investigating several mergers impacting shareholders of VYNE Therapeutics Inc., Masimo Corporation, Independent Bank Corporation, and HCB Financial Corp. The firm is encouraging shareholders to seek more information regarding the terms of these transactions, including the proposed ownership percentages for VYNE shareholders and the cash/stock considerations for Masimo, IBCP, and HCBN shareholders. They emphasize their track record in recovering money for shareholders and urge investors to contact them for a free consultation.
3 Reasons to Avoid DHR and 1 Stock to Buy Instead
This article recommends avoiding Danaher (DHR) due to concerns about its organic revenue growth, shrinking adjusted operating margin, and dropping free cash flow margin. The analysis suggests Danaher's core business is faltering and that its declining profitability and cash flow raise questions. Instead, the authors recommend other market-beating stocks, highlighting past recommendations like Nvidia and Kadant.
Quantum-Si (NASDAQ: QSI) plans 2026 virtual meeting and pay vote
Quantum-Si (NASDAQ: QSI) will hold its fully virtual 2026 annual shareholder meeting on May 15, 2026, at 1:00 p.m. Eastern, where stockholders will vote on electing ten directors, ratifying PricewaterhouseCoopers LLP as auditor, and approving a non-binding advisory say-on-pay for named executive officers. Founder Jonathan M. Rothberg, Ph.D., who beneficially owns all Class B shares, holds approximately 69.33% of the total voting power, effectively controlling the outcome of all proposals. The proxy statement details executive compensation for 2025, outstanding equity awards, and director compensation.
Worldwide Factors Influencing the Rapid Evolution of the Life Science Tools Market
The life science tools market is projected to reach $379.95 billion by 2030, growing at a CAGR of 13.5%. This growth is fueled by automation, increased investments in genomics and proteomics, demand for personalized medicine, and advancements in clinical diagnostics and drug discovery. Key players like F. Hoffmann-La Roche Ltd. and Thermo Fisher Scientific Inc. are driving innovation, exemplified by strategic acquisitions and the development of advanced sequencing platforms such as Illumina's MiSeq i100 series.
Key Factors and Emerging Trends Shaping the Lab Supplies Market Landscape
The lab supplies market is set to reach $60.9 billion by 2030, growing at an 8.5% CAGR, driven by advancements in life sciences, diagnostics, and automation. Key trends include increased demand for premium consumables, automated equipment, and a focus on safety and sustainability. Leading companies like Thermo Fisher Scientific and Danaher Corporation are innovating to enhance accuracy and efficiency, with acquisitions like Calibre Scientific's purchase of Dynalab Corp. expanding market reach and product portfolios.
Masimo (MASI) agrees to $180 cash takeover by Danaher; vote set May 1, 2026
Masimo Corporation has agreed to be acquired by Danaher Corporation for $180.00 per share in an all-cash merger, valuing Masimo at approximately $9.26 billion. The acquisition, which represents a 38% premium over Masimo's closing price on February 13, 2026, requires Masimo stockholder approval, with a special meeting scheduled for May 1, 2026. The Masimo Board unanimously recommends stockholders vote "FOR" the merger.
Live Cell Imaging Market Set to Boom Rapidly by 2033| Thermo Fisher Scientific Inc. • Merck KgaA • PerkinElmer Inc
The Live Cell Imaging market is expected to grow significantly, from US$ 1,924.4 Mn in 2025 to US$ 2,921.9 Mn by 2032, at a CAGR of 7.2%. This report provides an in-depth analysis of market dynamics, key players such as Thermo Fisher Scientific, Merck KgaA, and PerkinElmer Inc., regional trends, and growth opportunities with forecasts up to 2033. It serves as a strategic guide for stakeholders with competitive analysis, market segmentation, and crucial insights to foster sustainable growth.
Key Factors and Emerging Trends Shaping the Life Science and Chemical Instrumentation Market Landscape
The life science and chemical instrumentation market is projected to reach $90.58 billion by 2030, driven by advanced omics technologies, personalized medicine research, and digital laboratories. Key trends include automated analytical instruments, high-throughput testing, and enhanced integration of laboratory information management systems, with major players like Agilent Technologies and Thermo Fisher Scientific leading innovation. Recent acquisitions, such as Spectris acquiring Micromeritics, highlight strategic moves to expand portfolios and leverage specialized expertise in this rapidly evolving sector.
Top Players and Market Competition in the In Situ Hybridization Industry
The in situ hybridization market is projected to reach $3.08 billion by 2030, growing at an 11.3% CAGR, driven by personalized medicine, AI-driven analysis, and genomic research. Key players like Thermo Fisher Scientific and Danaher Corporation are shaping the industry, with a focus on innovations such as Hybridization Chain Reaction RNA Chromogenic in situ Hybridization (HCR RNA-CISH). The market is segmented by product types, techniques, probe types, applications, and end-users, highlighting its specialized and evolving nature.
Infectious Disease Diagnostics Testing Market Overview, Key Trends, and Major Player Analysis
The infectious disease diagnostics testing market is projected to reach $65.49 billion by 2030, growing at a CAGR of 9.0%. This growth is driven by increasing global health challenges, demand for rapid diagnostic tools, and investments in healthcare. Key trends include stronger demand for early detection, wider adoption of point-of-care testing, and increased use of molecular diagnostics.
Nisa Investment Advisors LLC Raises Stock Holdings in Danaher Corporation $DHR
Nisa Investment Advisors LLC has increased its stake in Danaher Corporation (NYSE: DHR) by 3.3% to 205,372 shares, valued at approximately $47.08 million. Other institutional investors also adjusted their positions, and hedge funds and institutional investors collectively own 79.05% of the company. Danaher recently increased its quarterly dividend to $0.40 per share and beat quarterly earnings and revenue estimates.
Danaher Corporation $DHR Shares Purchased by Capital Advisors Inc. OK
Capital Advisors Inc. OK increased its stake in Danaher Corporation by 6.4%, acquiring an additional 13,796 shares and bringing its total holdings to 230,926 shares valued at $52.86 million. Danaher reported strong Q4 earnings, surpassing analyst estimates with $2.23 EPS and $6.84 billion in revenue. The company also raised its quarterly dividend to $0.40 per share, resulting in a 0.8% yield, and analysts maintain a "Moderate Buy" rating with an average target price of $253.55.
Allspring Global Investments Holdings LLC Acquires 38,979 Shares of Danaher Corporation $DHR
Allspring Global Investments Holdings LLC increased its stake in Danaher Corporation by 8.7% in the fourth quarter, purchasing an additional 38,979 shares to own a total of 485,461 shares valued at $111.85 million. Other institutional investors also made significant buys, while an insider, EVP Gregory M. Milosevich, sold 1,320 shares. Analysts have maintained a "Moderate Buy" consensus rating with an average price target of $253.55 for Danaher.
Thermo Fisher’s Glacios 3 Cryo TEM Puts AI At Center Of Growth
Thermo Fisher Scientific recently unveiled its Glacios 3 Cryo-TEM, an advanced cryo electron microscope incorporating AI-supported tools and improved imaging clarity. This new system is designed to accelerate drug discovery and structural studies by reducing practical barriers to adoption. For investors, the launch represents a significant product milestone for the company, highlighting its focus on high-impact analytical tools and AI in drug development.
Danaher Corp. Experiences Revision in Stock Evaluation Amid Market Volatility
Danaher Corp., a key player in the Pharmaceuticals & Biotechnology sector, has recently undergone a stock evaluation revision due to significant market volatility. The company's stock price has declined, trading at $181.52, and its performance has consistently lagged behind the S&P 500 across various time frames. Technical indicators suggest a prevailing bearish sentiment, highlighting ongoing market challenges for Danaher.
Does Thermo Fisher’s New SHL Autoinjector Hub Reshape Its Device Integration Strategy For TMO?
Thermo Fisher Scientific has partnered with SHL Medical to establish an integrated U.S. hub for sterile fill-finish, autoinjector assembly, and commercial packaging, strengthening its role as an end-to-end partner for pharmaceutical and biotech companies. This collaboration, featuring SHL Medical's Molly autoinjector platform, aims to enhance Thermo Fisher's biopharma services, complementing its global sterile manufacturing network. While this move supports Thermo Fisher's long-term growth and high-value services, investors should also consider external risks like tariffs, policy shifts, and a growing dependence on acquisitions.
Thermo Fisher Scientific Stock: Leading Life Sciences Provider Faces Mixed Institutional Flows Amid Strong Fundamentals
Thermo Fisher Scientific, a global leader in life sciences, reported strong quarterly results in January 2026, beating earnings expectations with significant revenue growth. Despite high institutional ownership and bullish analyst ratings, some investors have trimmed stakes, signaling caution. The company shows strong financials, dividend growth potential, and strategic developments, making it a key play for North American investors in healthcare innovation.
Danaher Corp. stock outperforms competitors on strong trading day
Danaher Corp. (DHR) shares rose 3.11% to $189.60 on Tuesday, outperforming the broader market. This occurred during a strong trading session where the S&P 500 Index increased by 2.91% and the Dow Jones Industrial Average rose by 2.49%. This marks the second consecutive day of gains for Danaher's stock.
Abbott Oncology Integration Into OncoEMR Tests Long Term Growth Story
Abbott Laboratories is integrating its Precision Oncology portfolio into Flatiron Health's OncoEMR platform, aiming to simplify cancer diagnostics for clinicians across 1,600+ U.S. community cancer centers. This move follows Abbott's expansion into cancer diagnostics through its Exact Sciences deal and seeks to improve distribution and workflow integration of its oncology tests. Investors will need to watch clinician adoption and the overall impact on Abbott's long-term growth story, especially considering mixed past share price performance.
Danaher Stock Is Down 20% in 2026. Here’s Why Analysts Still See a $239 Target
Danaher Corporation (DHR) stock has dropped nearly 20% in 2026, largely influenced by its $9.9 billion acquisition of Masimo, which caused investor concerns about the company's strategic direction. Despite this, analysts still project a target price of $239, implying a nearly 30% upside. The valuation model expects 9.9% annualized returns over the next 2.7 years, contingent on the company achieving anticipated revenue growth, margin improvement, and successful integration of the Masimo acquisition.
SNP Genotyping and Analysis Market to See Booming Growth
The SNP Genotyping and Analysis Market is anticipated to experience significant growth from 2026 to 2033, driven by increasing industry demand and technological advancements. A new report by Coherent Market Insights offers a comprehensive analysis of market size, revenue trends, key growth factors, and competitive landscapes. The report aims to provide stakeholders with actionable insights for informed, data-driven decisions amidst global market dynamics.
Large Scale Plasma Separation Market Is Going to Boom | Merck KGaA
Coherent Market Insights has released a comprehensive report titled "Large Scale Plasma Separation Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033". The report analyzes market competition, geographic distribution, and growth potential, providing crucial insights for entrepreneurs, investors, researchers, and business strategists. It details industry performance, identifies key success factors, assesses risks, and projects economic analysis, ROI, and profit margins.
Northstar Advisory Group LLC Acquires New Shares in Danaher Corporation $DHR
Northstar Advisory Group LLC has acquired a new position in Danaher Corporation (NYSE:DHR) during the fourth quarter, purchasing 14,775 shares valued at approximately $3.38 million. This investment represents 1.2% of Northstar's portfolio and makes Danaher its 26th largest holding. The acquisition comes as Danaher reported strong Q4 earnings, expects continued growth, recently increased its quarterly dividend, and holds a "Moderate Buy" consensus rating from analysts.
J. Safra Sarasin Holding AG Has $31.57 Million Stake in Danaher Corporation $DHR
J. Safra Sarasin Holding AG increased its stake in Danaher Corporation (NYSE:DHR) by 28.2% to $31.57 million during the fourth quarter. Other institutional investors like Viking Global Investors LP and Generation Investment Management LLP also significantly boosted their holdings. Danaher recently reported strong quarterly earnings, exceeding analyst expectations, and increased its quarterly dividend.
Mn Services Vermogensbeheer B.V. Acquires 5,736 Shares of Danaher Corporation $DHR
Mn Services Vermogensbeheer B.V. increased its stake in Danaher Corporation by 2.4% in the fourth quarter, acquiring 5,736 shares and bringing its total holdings to 249,336 shares valued at $57.08 million. Danaher also announced an increase in its quarterly dividend to $0.40 per share, resulting in an annualized payout of $1.60 and a yield of approximately 0.9%. Despite an executive's recent sale of shares, institutional investors now own 79.05% of the stock.
Bio-Techne’s New COMET Spatial Tools Might Change The Case For Investing In Bio-Techne (TECH)
Bio-Techne has expanded its COMET spatial biology portfolio with new SPYRE Focus Panels, Amplification Kits, and upgraded HORIZON software, which could significantly enhance automated, high-plex tissue analysis. This innovation strengthens Bio-Techne's position in high-content, automated analysis for complex diseases, aligning with precision medicine trends. Despite potential near-term risks from biotech funding and tariffs, these advancements could positively influence the company's investment narrative, offering a potential 45% upside to its current price according to some fair value estimates.
Is Danaher’s BIO-Europe Spring Focus Sharpening Its Life Sciences Edge or Simply Polishing the Story (DHR)?
Danaher Corporation presented at the BIO-Europe Spring 2026 conference, highlighting its life sciences tools and diagnostics capabilities to potential collaborators. While this appearance boosts their narrative, it doesn't immediately address key challenges like the recovery of early-stage biotech demand or policy pressures in China. Investors are also considering the company's recent dividend increase and a wide range of fair value estimates.
